Schedule of Investments

ARK Genomic Revolution ETF

October 31, 2022 (Unaudited)

Investments	Shares		Value
COMMON STOCKS–99.3%
Biotechnology - 57.7%
Arcturus Therapeutics Holdings, Inc.*†		2,088,857	$	36,972,769
Beam Therapeutics, Inc.*		1,970,213		86,807,585
CareDx, Inc.*†		6,144,149		122,330,007
Compass Pathways PLC (United Kingdom)*(a)		1,047,431		11,039,923
CRISPR Therapeutics AG (Switzerland)*		1,603,225		83,912,797
Exact Sciences Corp.*		4,679,848		162,765,113
Fate Therapeutics, Inc.*		4,035,186		84,416,091
Incyte Corp.*		986,181		73,312,696
Intellia Therapeutics, Inc.*		1,720,411		90,803,293
Ionis Pharmaceuticals, Inc.*		3,205,329		141,675,542
Iovance Biotherapeutics, Inc.*		2,218,608		20,721,799
Moderna, Inc.*		156,587		23,539,724
Nurix Therapeutics, Inc.*		2,062,915		26,260,908
Organovo Holdings, Inc.*		174,266		285,796
Prime Medicine, Inc.*		1,256,473		23,646,822
Recursion Pharmaceuticals, Inc., Class A*		3,216,966		33,938,991
Regeneron Pharmaceuticals, Inc.*		35,257		26,398,679
Repare Therapeutics, Inc. (Canada)*†		2,520,030		37,951,652
Senti Biosciences, Inc.*		1,996,698		4,632,339
Senti Biosciences, Inc.*,(b)		243,471		508,367
Surface Oncology, Inc.*†		5,822,877		7,220,367
Twist Bioscience Corp.*		2,352,416		77,229,817
Veracyte, Inc.*		2,332,181		46,900,160
Vertex Pharmaceuticals, Inc.*		150,643		47,000,616
Verve Therapeutics, Inc.*		2,363,325		89,097,352
Total Biotechnology				1,359,369,205
Chemicals - 4.5%
Ginkgo Bioworks Holdings, Inc.*		38,846,885		106,051,996
Electronic Equipment, Instruments & Components - 2.5%
908 Devices, Inc.*†		3,614,707		57,799,165
Health Care Equipment & Supplies - 2.8%
Butterfly Network, Inc.*†		10,380,379		50,863,857
Cerus Corp.*		3,846,064		14,076,594
Total Health Care Equipment & Supplies				64,940,451
Health Care Providers & Services - 4.8%
Accolade, Inc.*†		5,664,774		61,066,264
Guardant Health, Inc.*		519,121		25,696,489
Invitae Corp.*		5,286,238		13,638,494
Signify Health, Inc., Class A*		446,356		13,046,986
Total Health Care Providers & Services				113,448,233
Health Care Technology - 9.8%
Schrodinger, Inc.*†		3,680,541		88,222,568
Teladoc Health, Inc.*		3,632,422		107,664,988
Veeva Systems, Inc., Class A*		219,488		36,860,815
Total Health Care Technology				232,748,371
Life Sciences Tools & Services - 12.7%
10X Genomics, Inc., Class A*		885,682		24,072,837
Adaptive Biotechnologies Corp.*†		9,087,728		70,702,524
Berkeley Lights, Inc.*		2,866,466		6,363,554
Codexis, Inc.*†		4,091,287		22,993,033
Pacific Biosciences of California, Inc.*†		11,696,488		98,718,359
Personalis, Inc.*†		5,268,887		14,067,928
Quantum-Si, Inc.*†		10,789,890		32,693,366
SomaLogic, Inc.*		9,113,059		31,622,315
Total Life Sciences Tools & Services				301,233,916
Pharmaceuticals - 1.8%
ATAI Life Sciences NV (Germany)*		5,879,928		17,345,788
Pfizer, Inc.		509,704		23,726,721
Total Pharmaceuticals				41,072,509
Semiconductors & Semiconductor Equipment - 1.0%
NVIDIA Corp.		180,549		24,368,699
Software - 1.7%
UiPath, Inc., Class A*		3,207,434		40,574,040
Total Common Stocks (Cost $6,740,023,773)				2,341,606,585
MONEY MARKET FUND–0.4%
Dreyfus Government Cash Management Fund, Institutional Shares, 2.91% (c) (Cost $8,728,898)		8,728,898		8,728,898
Total Investments–99.7% (Cost $6,748,752,671)				2,350,335,483
Other Assets in Excess of Liabilities–0.3%				7,214,431
Net Assets–100.0%			$	2,357,549,914

†	Affiliated security
*	Non-income producing security
(a)	American Depositary Receipt
(b)	Restricted security; security may not be publicly sold without registration under the Securities Act of 1933, as amended. As of October 31, 2022, total investments in restricted securities were $508,367 and are classified as Level 2.
(c)	Rate shown represents annualized 7-day yield as of October 31, 2022.

Schedule of Investments (continued)

ARK Genomic Revolution ETF

October 31, 2022 (Unaudited)

Affiliated Issuer Transactions

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period to date transactions with companies which are or were affiliates are as follows:

	Value ($) at 7/31/2022		Purchases Cost ($)		Sales Proceeds ($)			Net Realized Gain/(Loss) ($)			Net Change in Unrealized Appreciation (Depreciation) ($)			Dividend Income ($)		Capital Gain Distributions ($)		Number of Shares at 10/31/2022		Value ($) at 10/31/2022
Common Stocks — 29.8%
Biotechnology — 8.7%
Arcturus Therapeutics Holdings, Inc.
		39,811,175		5,421,704		(8,131,509	)		(3,542,651	)		3,414,050			–		–		2,088,857		36,972,769
CareDx, Inc.
		104,441,573		54,816,421		(22,808,828	)		433,141			(14,552,300	)		–		–		6,144,149		122,330,007
Repare Therapeutics, Inc.
		34,591,003		5,063,160		(7,722,555	)		(3,387,616	)		9,407,660			–		–		2,520,030		37,951,652
Surface Oncology, Inc.
		10,813,242		1,259,319		(1,864,171	)		(310,858	)		(2,677,165	)		–		–		5,822,877		7,220,367
Chemicals — 0.0%
Zymergen, Inc.  ^
		19,213,895		2,867,953		(20,336,476	)		(46,330,747	)		44,585,375			–		–		–		–
Electronic Equipment, Instruments & Components — 2.5%
908 Devices, Inc.
		80,344,058		17,093,088		(14,883,098	)		(912,631	)		(23,842,252	)		–		–		3,614,707		57,799,165
Health Care Equipment & Supplies — 2.2%
Butterfly Network, Inc.
		36,949,002		23,594,482		(12,554,070	)		3,236,958			(362,515	)		–		–		10,380,379		50,863,857
Health Care Providers & Services — 2.6%
Accolade, Inc.
		56,841,976		10,456,393		(15,809,588	)		6,210,551			3,366,932			–		–		5,664,774		61,066,264
Health Care Technology — 3.7%
Schrodinger, Inc.
		107,424,667		31,588,266		(22,811,203	)		(615,484	)		(27,363,678	)		–		–		3,680,541		88,222,568
Life Sciences Tools & Services — 10.1%
Adaptive Biotechnologies Corp.
		79,152,238		24,186,884		(17,856,957	)		529,531			(15,309,172	)		–		–		9,087,728		70,702,524
Codexis, Inc.
		30,479,069		4,468,262		(6,648,050	)		(1,519,535	)		(3,786,713	)		–		–		4,091,287		22,993,033
Pacific Biosciences of California, Inc.
		52,499,699		16,465,013		(18,165,406	)		(951,643	)		48,870,696			–		–		11,696,488		98,718,359
Personalis, Inc.
		19,984,442		4,100,784		(4,334,247	)		(336,109	)		(5,346,942	)		–		–		5,268,887		14,067,928
Quantum-Si, Inc.
		37,961,956		5,564,210		(8,184,287	)		(2,245,850	)		(402,663	)		–		–		10,789,890		32,693,366
	$	710,507,995	$	206,945,939	$	(182,110,445	)	$	(49,742,943	)	$	16,001,313		$	–	$	–		80,850,594	$	701,601,859

^ As of October 31, 2022, the company was no longer considered to be an affiliated security.

Fair Value Measurement

The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• Level 1 — Quoted prices in active markets for identical assets.

• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the valuations as of October 31, 2022, based upon the three levels defined above:

Schedule of Investments (continued)

ARK Genomic Revolution ETF

October 31, 2022 (Unaudited)

ARK Genomic Revolution ETF	Level 1		Level 2		Level 3		Total
Assets
Common Stocks‡	$	2,341,098,218	$	508,367	$	–	$	2,341,606,585
Money Market Fund		8,728,898		–		–		8,728,898
Total	$	2,349,827,116	$	508,367	$	–	$	2,350,335,483

‡ Please refer to the Schedule of Investments to view securities segregated by industry type.